Schonfeld Strategic Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.72M	Buy	296,431 +61,708	+26%	+$409K	0.01%	884
2025 Q4	$1.84M	Sell	234,723 -69,781	-23%	-$549K	0.01%	904
2025 Q3	$2.48M	Sell	304,504 -84,562	-22%	-$562K	0.01%	923
2025 Q2	$1.82M	Sell	389,066 -211,101	-35%	-$967K	0.01%	1037
2025 Q1	$3.29M	Buy	600,167 +497,167	+483%	+$2.01M	0.02%	703
2024 Q4	$349K	Sell	103,000 -69,327	-40%	-$223K	﹤0.01%	1549
2024 Q3	$491K	Sell	172,327 -163,720	-49%	-$420K	﹤0.01%	1442
2024 Q2	$756K	Buy	336,047 +45,549	+16%	+$91.8K	﹤0.01%	1322
2024 Q1	$642K	Buy	+290,498	New	+$752K	﹤0.01%	1386
2023 Q3	–	Sell	-25,800	Closed	-$67.6K	–	2362
2023 Q2	$67.6K	Buy	+25,800	New	+$65.7K	﹤0.01%	1783
2022 Q2	–	Sell	-12,500	Closed	-$32K	–	3057
2022 Q1	$32K	Buy	+12,500	New	+$30.5K	﹤0.01%	2374

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schonfeld Strategic Advisors's XERS Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Xeris Biopharma Holdings (XERS) stake by 26% in Q1 2026, buying an estimated $409K and bringing the position to 296,431 shares worth $1.72M. The position accounts for 0.01% of the portfolio, ranked #884.

Schonfeld Strategic Advisors first reported a position in XERS in Q1 2022 and has held it in 11 quarters since. The position peaked at $3.29M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Schonfeld Strategic Advisors held 296,431 shares of Xeris Biopharma Holdings worth $1.72M as of Q1 2026.
Schonfeld Strategic Advisors bought 61,708 Xeris Biopharma Holdings shares in Q1 2026, an estimated $409K.
Xeris Biopharma Holdings made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #884 holding.
Schonfeld Strategic Advisors first reported a position in Xeris Biopharma Holdings in Q1 2022 and has held it in 11 quarters since.
Schonfeld Strategic Advisors's Xeris Biopharma Holdings position peaked at $3.29M in Q1 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.